SCHEDULE: Vanguard Discloses 5.26% Stake in Avalo Therapeutics

The Vanguard Group has reported a passive 5.26% beneficial ownership stake in Avalo Therapeutics Inc. common stock.

Summary

• The Vanguard Group beneficially owns 692,637 shares of Avalo Therapeutics Inc. common stock.
• This ownership represents 5.26% of the company's outstanding common stock.
• Vanguard holds sole dispositive power over 631,232 shares and shared dispositive power over 61,405 shares.
• Vanguard holds shared voting power over 55,800 shares and no sole voting power.
• The stake was acquired and is held in the ordinary course of business, not for the purpose of changing or influencing control of Avalo Therapeutics.

Sentiment

Score: 5

Explanation: This is a neutral, factual disclosure of beneficial ownership by a large institutional investor, providing no direct positive or negative sentiment regarding the issuer's performance or prospects.

Future Outlook

NA

Industry Context

This filing indicates a significant passive investment by a major institutional asset manager, The Vanguard Group, in Avalo Therapeutics, a biotechnology company. Such a stake is common for large index funds or passively managed portfolios, reflecting the company's inclusion in relevant market indices.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, potentially increasing confidence due to Vanguard's presence.
• Company Management: Awareness of a large, passive institutional investor, which typically implies a long-term, non-activist shareholder base.

Key Dates

Keywords

Avalo Therapeutics, Vanguard Group, Schedule 13G, Common Stock, Beneficial Ownership, Institutional Investor, Biotechnology, Healthcare